Data / Drug companies / Solco Healthcare US, LLC
Solco Healthcare US, LLC: 259 products in the FDA NDC directory, labeler code 43547
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Solco Healthcare US, LLC (labeler code 43547) lists 259 products in the FDA National Drug Code Directory, covering 74 finished drugs by generic name. By type: 259 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on August 17, 2026.
The request: Watch Solco Healthcare US, LLC (FDA labeler code 43547): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 43547
- Products in commercial distribution
- 259
- Packages
- 636
- Finished drugs by generic name
- 74
- Prescription products
- 259
- Over the counter products
- 0
- Controlled substance products
- Schedule II 12, Schedule III 1, Schedule IV 8, Schedule V 8
- Flagged as original packager
- 241 of 241 products that carry the flag
- Started marketing in the last 12 months
- 7
- Earliest marketing start
- January 4, 2002
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 259 | 100% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 259 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 138 | 53.3% |
| Tablet, film coated | 49 | 18.9% |
| Capsule | 27 | 10.4% |
| Tablet, extended release | 13 | 5% |
| Injection | 7 | 2.7% |
| Capsule, delayed release | 7 | 2.7% |
| Tablet, coated | 6 | 2.3% |
| Tablet, film coated, extended release | 5 | 1.9% |
| Tablet, delayed release | 3 | 1.2% |
| Capsule, extended release | 2 | 0.8% |
| Injection, powder, for solution | 1 | 0.4% |
| Ointment | 1 | 0.4% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Hydrocortisone | 43547-894 | Tablet | Generic drugs (ANDA) | August 17, 2026 |
| Hydrocortisone | 43547-893 | Tablet | Generic drugs (ANDA) | August 17, 2026 |
| Hydrocortisone | 43547-892 | Tablet | Generic drugs (ANDA) | August 17, 2026 |
| Gabapentin | 43547-481 | Capsule | Generic drugs (ANDA) | April 29, 2026 |
| Gabapentin | 43547-480 | Capsule | Generic drugs (ANDA) | April 29, 2026 |
| Gabapentin | 43547-479 | Capsule | Generic drugs (ANDA) | April 29, 2026 |
| Doxycycline | 43547-590 | Capsule | Generic drugs (ANDA) | December 15, 2025 |
| Nitroglycerin | 43547-987 | Tablet | Generic drugs (ANDA) | June 1, 2025 |
| Nitroglycerin | 43547-986 | Tablet | Generic drugs (ANDA) | June 1, 2025 |
| Nitroglycerin | 43547-985 | Tablet | Generic drugs (ANDA) | June 1, 2025 |
| Ticagrelor | 43547-657 | Tablet, film coated | Generic drugs (ANDA) | April 1, 2025 |
| Bumetanide | 43547-898 | Tablet | Generic drugs (ANDA) | March 1, 2025 |
| Bumetanide | 43547-897 | Tablet | Generic drugs (ANDA) | March 1, 2025 |
| Bumetanide | 43547-896 | Tablet | Generic drugs (ANDA) | March 1, 2025 |
| Tadalafil | 43547-032 | Tablet | Generic drugs (ANDA) | November 27, 2024 |
| Tadalafil | 43547-031 | Tablet | Generic drugs (ANDA) | November 27, 2024 |
| Tadalafil | 43547-030 | Tablet | Generic drugs (ANDA) | November 27, 2024 |
| Levetiracetam | 43547-880 | Tablet, film coated | Generic drugs (ANDA) | September 1, 2024 |
| Pemetrexed | 43547-632 | Injection, powder, for solution | Generic drugs (ANDA) | July 1, 2024 |
| Butalbital, acetaminophen and caffeine | 43547-686 | Capsule | Generic drugs (ANDA) | December 5, 2023 |
| Ciprofloxacin | 43547-689 | Tablet | Generic drugs (ANDA) | October 1, 2023 |
| Ciprofloxacin | 43547-688 | Tablet | Generic drugs (ANDA) | October 1, 2023 |
| Lisdexamfetamine dimesylate | 43547-608 | Capsule | Generic drugs (ANDA) | August 26, 2023 |
| Lisdexamfetamine dimesylate | 43547-607 | Capsule | Generic drugs (ANDA) | August 26, 2023 |
| Lisdexamfetamine dimesylate | 43547-606 | Capsule | Generic drugs (ANDA) | August 26, 2023 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.